vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Dolby Laboratories, Inc. (DLB). Click either name above to swap in a different company.
Dolby Laboratories, Inc. is the larger business by last-quarter revenue ($395.6M vs $284.0M, roughly 1.4× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 24.0%, a 72.3% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs 7.1%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 13.9%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Dolby Laboratories, Inc. is an American technology corporation specializing in audio noise reduction, audio encoding/compression, spatial audio, and high-dynamic-range television (HDR) imaging. Dolby licenses its technologies to consumer electronics manufacturers.
ACAD vs DLB — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $395.6M |
| Net Profit | $273.6M | $94.9M |
| Gross Margin | 90.8% | 88.7% |
| Operating Margin | 6.1% | 28.5% |
| Net Margin | 96.3% | 24.0% |
| Revenue YoY | 9.4% | 7.1% |
| Net Profit YoY | 90.3% | 3.4% |
| EPS (diluted) | $1.61 | $0.99 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | — | $395.6M | ||
| Q1 26 | — | $346.7M | ||
| Q4 25 | $284.0M | $346.7M | ||
| Q3 25 | $278.6M | $307.0M | ||
| Q2 25 | $264.6M | $315.5M | ||
| Q1 25 | $244.3M | $369.6M | ||
| Q4 24 | $259.6M | $357.0M | ||
| Q3 24 | $250.4M | $304.8M |
| Q2 26 | — | $94.9M | ||
| Q1 26 | — | $53.3M | ||
| Q4 25 | $273.6M | $53.3M | ||
| Q3 25 | $71.8M | $49.3M | ||
| Q2 25 | $26.7M | $46.1M | ||
| Q1 25 | $19.0M | $91.8M | ||
| Q4 24 | $143.7M | $67.8M | ||
| Q3 24 | $32.8M | $58.6M |
| Q2 26 | — | 88.7% | ||
| Q1 26 | — | 87.5% | ||
| Q4 25 | 90.8% | 87.5% | ||
| Q3 25 | 92.2% | 87.1% | ||
| Q2 25 | 92.2% | 86.1% | ||
| Q1 25 | 91.7% | 90.3% | ||
| Q4 24 | 91.6% | 88.6% | ||
| Q3 24 | 92.5% | 88.8% |
| Q2 26 | — | 28.5% | ||
| Q1 26 | — | 17.9% | ||
| Q4 25 | 6.1% | 17.9% | ||
| Q3 25 | 12.8% | 9.7% | ||
| Q2 25 | 12.2% | 15.1% | ||
| Q1 25 | 7.9% | 29.2% | ||
| Q4 24 | 59.1% | 22.4% | ||
| Q3 24 | 12.6% | 15.2% |
| Q2 26 | — | 24.0% | ||
| Q1 26 | — | 15.4% | ||
| Q4 25 | 96.3% | 15.4% | ||
| Q3 25 | 25.8% | 16.1% | ||
| Q2 25 | 10.1% | 14.6% | ||
| Q1 25 | 7.8% | 24.8% | ||
| Q4 24 | 55.4% | 19.0% | ||
| Q3 24 | 13.1% | 19.2% |
| Q2 26 | — | $0.99 | ||
| Q1 26 | — | $0.55 | ||
| Q4 25 | $1.61 | $0.55 | ||
| Q3 25 | $0.42 | $0.50 | ||
| Q2 25 | $0.16 | $0.48 | ||
| Q1 25 | $0.11 | $0.94 | ||
| Q4 24 | $0.86 | $0.70 | ||
| Q3 24 | $0.20 | $0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $594.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $2.6B |
| Total Assets | $1.6B | $3.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | $594.7M | ||
| Q1 26 | — | $644.6M | ||
| Q4 25 | $177.7M | $644.6M | ||
| Q3 25 | $258.0M | $702.6M | ||
| Q2 25 | $253.6M | $699.3M | ||
| Q1 25 | $217.7M | $626.6M | ||
| Q4 24 | $319.6M | $520.8M | ||
| Q3 24 | $155.1M | $482.0M |
| Q2 26 | — | $2.6B | ||
| Q1 26 | — | $2.6B | ||
| Q4 25 | $1.2B | $2.6B | ||
| Q3 25 | $917.3M | $2.6B | ||
| Q2 25 | $822.4M | $2.6B | ||
| Q1 25 | $765.2M | $2.6B | ||
| Q4 24 | $732.8M | $2.5B | ||
| Q3 24 | $577.2M | $2.5B |
| Q2 26 | — | $3.2B | ||
| Q1 26 | — | $3.2B | ||
| Q4 25 | $1.6B | $3.2B | ||
| Q3 25 | $1.3B | $3.2B | ||
| Q2 25 | $1.2B | $3.2B | ||
| Q1 25 | $1.1B | $3.2B | ||
| Q4 24 | $1.2B | $3.2B | ||
| Q3 24 | $976.9M | $3.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $147.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -0.18× | 1.55× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | $147.3M | ||
| Q1 26 | — | $54.8M | ||
| Q4 25 | $-48.7M | $54.8M | ||
| Q3 25 | $74.3M | $472.2M | ||
| Q2 25 | $64.0M | $67.7M | ||
| Q1 25 | $20.3M | $174.9M | ||
| Q4 24 | $40.4M | $106.8M | ||
| Q3 24 | $63.2M | $327.3M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | $50.2M | ||
| Q3 25 | $73.9M | $435.9M | ||
| Q2 25 | — | $61.3M | ||
| Q1 25 | — | $168.0M | ||
| Q4 24 | — | $100.0M | ||
| Q3 24 | $63.2M | $297.2M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | 14.5% | ||
| Q3 25 | 26.5% | 142.0% | ||
| Q2 25 | — | 19.4% | ||
| Q1 25 | — | 45.5% | ||
| Q4 24 | — | 28.0% | ||
| Q3 24 | 25.2% | 97.5% |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | 1.3% | ||
| Q3 25 | 0.1% | 11.8% | ||
| Q2 25 | — | 2.0% | ||
| Q1 25 | — | 1.9% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | 0.0% | 9.8% |
| Q2 26 | — | 1.55× | ||
| Q1 26 | — | 1.03× | ||
| Q4 25 | -0.18× | 1.03× | ||
| Q3 25 | 1.03× | 9.57× | ||
| Q2 25 | 2.40× | 1.47× | ||
| Q1 25 | 1.07× | 1.91× | ||
| Q4 24 | 0.28× | 1.57× | ||
| Q3 24 | 1.93× | 5.59× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
DLB
| Licensing | $372.2M | 94% |
| Products and services | $23.4M | 6% |
